Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A synthetic heptapeptide analog of ACTH(4-10) developed in Russia, where it has been used clinically for decades to treat cerebral ischemia and cognitive impairment. Growing interest in the West for nootropic and neuroprotective applications.
A synthetic heptapeptide analog of tuftsin developed by the Institute of Molecular Genetics in Russia. Approved in Russia as an anxiolytic and nootropic. Widely used for anxiety reduction and cognitive enhancement without sedation.
Activates BDNF (brain-derived neurotrophic factor) and its receptor TrkB, promoting neuronal survival, synaptic plasticity, and cognitive function. Also modulates serotonergic, dopaminergic, and adrenergic systems. Reduces oxidative stress and neuroinflammation.
Modulates GABA-A receptor activity and increases BDNF expression. Stabilizes enkephalins (endogenous opioid peptides) by inhibiting their enzymatic breakdown, prolonging their anxiolytic effects. Also modulates serotonin, dopamine, and norepinephrine systems.
- Cognitive enhancement and focus
- Neuroprotection after stroke or ischemia
- Anxiety and depression support
- ADHD symptom management
- Memory and learning improvement
- Anxiety and stress reduction
- Cognitive enhancement and focus
- Depression support
- Immune system modulation
- Memory improvement
- Limited Western clinical trial data
- Nasal spray form may cause irritation
- Potential stimulant-like effects
- Headaches reported
- Long-term safety profile unknown in Western populations
- Limited Western clinical trial data
- Nasal spray may cause mild irritation
- Potential fatigue at higher doses
- Long-term safety profile not established in Western populations
- Interactions with other anxiolytics not well characterized
Removed from FDA 503A Category 2 effective April 22, 2026. Scheduled for PCAC review on July 24, 2026. Has extensive clinical use in Russia for cerebral ischemia and trigeminal neuralgia, but limited US clinical trial data. Compounding not yet authorized — status is in regulatory gray zone pending PCAC recommendation.
PCAC: July 24, 2026
Not FDA-approved and not currently on any FDA compounding list. Available as a research chemical. Approved in Russia as an anxiolytic drug. Not affected by the April 2026 Category 2 removal action.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.